Some useful links to MPN information resources, guidelines and detailed research articles are provided below.
Essential thrombocythemia (ET) specific information
Polycythemia Vera (PV) specific information
Myelofibrosis (MF) specific information
Myelofibrosis Stem Cell Transplant information
Pediatric and Young Adult MPNs
- US National Comprehensive Cancer Network (NCCN) Guidelines for Patients: Myeloproliferative Neoplasms – 2022
- Myeloproliferative neoplasms: Classifications and an approach to diagnosis, Australian Journal of General Practice, 2021
- Biology and therapeutic targeting of molecular mechanisms in MPNs, Blood, 2023
- WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: document summary and in-depth discussion
- Myeloproliferative neoplasms unclassifiable: how I manage – practical approaches for 2022 and beyond, BJH, 2022
- Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms , 2020
- COVID-19 – please refer to our COVID-19 specific page.
- Splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies, Critical review, AJH, 2023
- Splanchnic vein thrombosis – a national retrospective cohort study of MPN-SVT, courtesy of MPN Hub, 2022
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
- Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder, 2023
- Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers, PLOS, research article, 2022
- What are the key considerations in managing pregnancy in myeloproliferative neoplasms, Elisabetta Abruzzese – courtesy of MPN Hub, 2023
- Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET, Hemasphere, Letter, 2023
- Best practice recommendations for the management of MPN in pregnant patients, courtesy of MPN Hub, 2021
(Please note that these are not Australian guidelines and local Australian practices may differ.) - Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations, AJH, 2020
- How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy, BJH 2020
- Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden, 2022
Essential thrombocythemia (ET) specific information
- Site specific venous thrombosis in ET: impact on subsequent vascular events and survival, ‘Journal of thrombosis and haemostasis’, 2022
- Essential thrombocythemia: challenges in clinical practice and future prospects, Blood 2023
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management, USA
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet, 2021
- MPL-mutated essential thrombocythemia: a morphologic reappraisal, Blood Cancer Journal, 2018
- Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis, Platelets, 2022
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients, AJH, Research article, 2014
Polycythemia Vera (PV) specific information
- ‘Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 2023
- JAK2V617F allele burden in polycythemia vera: burden of proof, Blood, 2023
- Diagnostics and risk stratification for patients with polycythemia vera, Expert Roundtable Review, 2023
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, Leukemia, 2022
- Real world evaluation of association between elevated blood counts and thrombotic events: analysis of data from REVEAL study, 2022 (courtesy of MPN Hub)
- Appropriate management of polycythaemia vera with cytoreductive drug therapy – European LeukemiaNet recommendations, 2021
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival Leukemia’, 2021
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management, USA
- A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline, 2019
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis – A British Society for Haematology Guideline, 2018
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
Myelofibrosis (MF) specific information
- Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (myelofibrosis focus)
- Myelofibrosis, Blood, 2023
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety, Journal of Hematology and Oncology, 2023
- Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy, Leukemia and Lymphoma, 2023
- Primary myelofibrosis: 2021 update on diagnosis, risk stratification and management
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia, Journal of Hematology and Oncology, 2022
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study, Therapeutic Advances in Hematology, 2022
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis, Blood Cancer Journal, 2021
- Prefibrotic Myelofibrosis treatment information 2018
Myelofibrosis Stem Cell Transplant information
- How I treat transplant-eligible patients with myelofibrosis, Blood, 2023
- Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 2023
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms:
A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023 - Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
- Myelofibrosis Stem Cell Transplant (SCT) Timing Tool
- Survival following allogeneic transplant in patients with myelofibrosis
- FACT SHEETS are provided on all the main treatments available for Australian MPN patients. These are available in several languages.
- Articles on MPN treatment – this link includes:
– a conversation with an MPN specialist about how interferons work in MPN patients,
– comparison studies of interferon and hydroxyurea,
– efficacy and safety of myelofibrosis treatments,
– clinical trial outcomes from Australia and overseas, and
– new developments for myelofibrosis treatments.
- Life histories of myeloproliferative neoplasms inferred from phylogenies, Nature, 2022
- Genetic basis and molecular profiling in myeloproliferative neoplasms, Blood, 2023
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms, NEJM, 2018
- Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood, 2019
- ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera, Blood Advances (letter), 2022
- Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
- Genetics Home Reference – Your Guide to Understanding Genetic Conditions
- ET https://ghr.nlm.nih.gov/condition/essential-thrombocythemia
- PV https://ghr.nlm.nih.gov/condition/polycythemia-vera#resources
- MF https://ghr.nlm.nih.gov/condition/primary-myelofibrosis
Links to information on various genetic mutations
- JAK2 https://ghr.nlm.nih.gov/gene/JAK2
- CALR https://ghr.nlm.nih.gov/gene/CALR
- MPL https://ghr.nlm.nih.gov/gene/MPL#resources
- TET2 https://ghr.nlm.nih.gov/gene/TET2#conditions
Pediatric and Young Adult MPNs
- Weill Cornell Medicine Pediatric Myeloproliferative Neoplasm Program
- Characterization of myeloproliferative neoplasms in the paediatric and young adult population, BJH 2023
- Clinical features associated with thrombotic events in children with myeloproliferative neoplasms 2022
- Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs, Blood Advances, 2022
